Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Jobst Vascular Center
1934
mi
from 91732
Toledo, OH
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Jobst Vascular Center
1934
mi
from 91732
Toledo, OH
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Oklahoma Foundation for Cardiovascular Research
1164
mi
from 91732
Oklahoma City, OK
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Oklahoma Foundation for Cardiovascular Research
1164
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Lancaster General Hospital
2313
mi
from 91732
Lancaster, PA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Lancaster General Hospital
2313
mi
from 91732
Lancaster, PA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Temple University Health System
2375
mi
from 91732
Philadelphia, PA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Temple University Health System
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Allegheny General Hospital
2118
mi
from 91732
Pittsburgh, PA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Allegheny General Hospital
2118
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Sanford Clinical Research
1314
mi
from 91732
Sioux Falls, SD
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Sanford Clinical Research
1314
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Clinical Research Solutions, P.C.
1923
mi
from 91732
Knoxville, TN
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Clinical Research Solutions, P.C.
1923
mi
from 91732
Knoxville, TN
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Saint Thomas Research Institute, LLC
1763
mi
from 91732
Nashville, TN
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Saint Thomas Research Institute, LLC
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
The Methodist Hospital Research Institute
1357
mi
from 91732
Houston, TX
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
The Methodist Hospital Research Institute
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Scott and White Memoral Hospital
1218
mi
from 91732
Temple, TX
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Scott and White Memoral Hospital
1218
mi
from 91732
Temple, TX
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Virginia Commonwealth University
2269
mi
from 91732
Richmond, VA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Virginia Commonwealth University
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Swedish Medical Center
961
mi
from 91732
Seattle, WA
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Swedish Medical Center
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated:  7/8/2015
Medizinische Hochschule Hannover
5686
mi
from 91732
Hannover,
Rheos® Pivotal Trial
Rheos® Pivotal Trial: Rheos™ Baroreflex Hypertension Therapy System
Status: Enrolling
Updated: 7/8/2015
Medizinische Hochschule Hannover
5686
mi
from 91732
Hannover,
Click here to add this to my saved trials
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  7/13/2015
Novartis Investigative Site
2451
mi
from 91732
Mineola, NY
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 7/13/2015
Novartis Investigative Site
2451
mi
from 91732
Mineola, NY
Click here to add this to my saved trials
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  7/13/2015
Novartis Investigative Site
7513
mi
from 91732
Darlinghurst,
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 7/13/2015
Novartis Investigative Site
7513
mi
from 91732
Darlinghurst,
Click here to add this to my saved trials
Global DuoTrav® Study
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
Status: Enrolling
Updated:  7/13/2015
Contact Alcon Call Center for Trial Locations
1194
mi
from 91732
Fort Worth, TX
Global DuoTrav® Study
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
Status: Enrolling
Updated: 7/13/2015
Contact Alcon Call Center for Trial Locations
1194
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Status: Enrolling
Updated:  7/22/2015
Clinical Research Facility
31
mi
from 91732
Newport Beach, CA
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
Status: Enrolling
Updated: 7/22/2015
Clinical Research Facility
31
mi
from 91732
Newport Beach, CA
Click here to add this to my saved trials
FFA Hypertension and Inflammation in Lean and Obese Subjects
Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects
Status: Enrolling
Updated:  7/23/2015
Grady Memorial Hospital
1919
mi
from 91732
Atlanta, GA
FFA Hypertension and Inflammation in Lean and Obese Subjects
Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects
Status: Enrolling
Updated: 7/23/2015
Grady Memorial Hospital
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigator Site
1785
mi
from 91732
Birmingham, AL
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigator Site
1785
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
343
mi
from 91732
Phoenix, AZ
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative site
25
mi
from 91732
Los Angeles, CA
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative site
25
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
358
mi
from 91732
San Francisco, CA
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
358
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
2303
mi
from 91732
Weston, FL
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
2303
mi
from 91732
Weston, FL
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigator Site
1726
mi
from 91732
Chicago, IL
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigator Site
1726
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
1524
mi
from 91732
Rochester, MN
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
1570
mi
from 91732
St. Louis, MO
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
1570
mi
from 91732
St. Louis, MO
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
1291
mi
from 91732
Omaha, NE
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
1291
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
2451
mi
from 91732
Mineola, NY
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
2451
mi
from 91732
Mineola, NY
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis
2435
mi
from 91732
New York, NY
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis
2435
mi
from 91732
New York, NY
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
2199
mi
from 91732
Durham, NC
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
2199
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
1881
mi
from 91732
Cincinnati, OH
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
1881
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
2031
mi
from 91732
Cleveland, OH
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
2031
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
2031
mi
from 91732
Cleveland, OH
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
2031
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
1165
mi
from 91732
Oklahoma City, OK
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
1165
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
820
mi
from 91732
Tualatin, OR
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
820
mi
from 91732
Tualatin, OR
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis
2121
mi
from 91732
Pittsburgh, PA
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis
2121
mi
from 91732
Pittsburgh, PA
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
1357
mi
from 91732
Houston, TX
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
1357
mi
from 91732
Houston, TX
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
1726
mi
from 91732
Milwaulkee, WI
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
1726
mi
from 91732
Milwaulkee, WI
Click here to add this to my saved trials
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated:  7/24/2015
Novartis Investigative Site
6093
mi
from 91732
Wien,
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension
Status: Enrolling
Updated: 7/24/2015
Novartis Investigative Site
6093
mi
from 91732
Wien,
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
VA Connecticut Healthcare System
2485
mi
from 91732
West Haven, CT
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
VA Connecticut Healthcare System
2485
mi
from 91732
West Haven, CT
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
Johns Hopkins Sibley Memorial Hospital
2278
mi
from 91732
Washington,
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
Johns Hopkins Sibley Memorial Hospital
2278
mi
from 91732
Washington,
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
University of Miami
2320
mi
from 91732
Miami, FL
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
University of Miami
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
University of Mississippi Medical Center
1609
mi
from 91732
Jackson, MS
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
University of Mississippi Medical Center
1609
mi
from 91732
Jackson, MS
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
Rutgers New Jersey Medical School
2422
mi
from 91732
Newark, NJ
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
Rutgers New Jersey Medical School
2422
mi
from 91732
Newark, NJ
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
North Shore University Hospital
2448
mi
from 91732
Manhasset, NY
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
North Shore University Hospital
2448
mi
from 91732
Manhasset, NY
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
New York University Lagone Medical Center
2434
mi
from 91732
NYC, NY
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
New York University Lagone Medical Center
2434
mi
from 91732
NYC, NY
Click here to add this to my saved trials
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated:  7/28/2015
Albert Einstein Medical Center
2375
mi
from 91732
Philadelphia, PA
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Status: Enrolling
Updated: 7/28/2015
Albert Einstein Medical Center
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials